SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Volquardsen who wrote (652)10/16/1997 10:43:00 AM
From: Henry Volquardsen   of 1115
 
The study was conducted by Dr. Malcolm S. Mitchell, a world recognized melanoma authority, who is Director of the Center for Biological Therapy and Melanoma Research at the University of California, San Diego. In the trial, 16 patients who had advanced stage IV melanoma were given the vaccine. Increased immune activity was found in 10 of the 15 patients ultimately evaluated. Some patients immune activity increased 10 fold while others tripled. In addition in five of the patients the disease stabilized and then went into remission. Patient survivability increased from 8 to 12 months. The study also confirmed the safety of the vaccine.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News